This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cell Culture: The Market For Media, Sera And Reagents, 5th Edition





 

 

 

NEW YORK, May 8, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell Culture: The Market for Media, Sera and Reagents, 5th Edition http://www.reportlinker.com/p01172034/Cell-Culture-The-Market-for-Media-Sera-and-Reagents-5th-Edition .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategoryThe growth in biopharmaceuticals is creating an unprecedented increase in demand for cell culture products. Cell culture techniques have been used in biological sciences for more than 50 years; however, cell culture techniques have been applied to production systems for only about 26 years. The cell culture industry, which began in the late 1980s from the utilization of recombinant DNA technology and cell hybridization, is today a major underpinning of the biopharmaceutical market. The choice of cells to use in biopharmaceutical production depends on a number of factors, some technical and some economic. Bacteria and yeast, for instance, are relatively simple to grow. Each cell of a bacterium or yeast is an independent organism capable of its own metabolism. Yeasts and bacteria have fairly simple nutritional needs and grow well suspended in a liquid medium, as well as in large fermentors. This report is focused on cell culture used in the research and production of biopharmaceuticals. In the pharmaceutical industry, cell culture is a major foundation of biopharmaceutical development, bioprocessing and manufacturing. Biopharmaceutical products are developed from large, complex protein molecules, which require equally complex manufacturing methods and an array of analytical techniques. As growing cells for biopharmaceutical production is slow, expensive and complicated, optimizing cell culture development is of paramount concern to companies developing biopharmaceuticals. Forecasts and current market sizing are provided in three specific segments:

  • Media,
  • Sera, and
  • Reagents

In addition to a thorough discussion of the technologies and techniques currently employed and emerging in the cell culture area, Kalorama's exhaustive report provides specific information on:

  • Market Size, growth, and forecasts of Media market, Sera market and Reagent market through 2017
  • Market Share Estimate for Animal-Derived, Component Free Media
  • Market Share Estimate for Serum-Free Media
  • Market Share Estimate for Chemically-Defined
  • Competitive Market Share by leading supplier as of 2012
  • Estimated Market by Region ( North America, Europe, Asia U.S.)

Key Market Drivers and Restraints for suppliers, including discussions of biopharmaceutical pipelines, biomedical R&D directions, and the future of transgenic plant and animal production.Review of the various expression systems (Bacteria, Yeast, Insect, and Mammal) and the biopharmaceutical product manufactured by these systems Discussion of the preferences in media types vying for dominance in the market, including the following:

  • ADCF - animal derived component free media
  • CD - chemically defined media
  • CSFM - complete serum free medium
  • PF - protein free media
  • SF - serum free media
  • SFM - serum free medium

Major Trends Impacting the Market: stem cell research (including plans of major companies), cell culture-based vaccine Production and generic biopharmaceuticals Profiles of Leading Suppliers and information about M&A activities in recent years .

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASDAQ 4,527.6890 -52.10 -1.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs